Overview

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Ipsen

Treatments:

Megestrol
Megestrol Acetate